

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 31/19, 31/21, 31/40</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/21246</b> <b>(43) International Publication Date:</b> 29 September 1994 (29.09.94)
<b>(21) International Application Number:</b> PCT/US94/02786 <b>(22) International Filing Date:</b> 15 March 1994 (15.03.94) <b>(30) Priority Data:</b> 032,366 17 March 1993 (17.03.93) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 032,366 (CON) Filed on 17 March 1993 (17.03.93) <b>(71) Applicant (for all designated States except US):</b> MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> DOLLERUP, Jens [DK/DK]; Blomstervaenget 40, DK-2800 Lyngby (DK). <b>(74) Agent:</b> DANIEL, Mark, R.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		<b>(81) Designated States:</b> AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> USE OF NON-STEROIDAL ANTIINFLAMMATORY AGENTS IN MACULAR DEGENERATION  <b>(57) Abstract</b>  Topically applied non-steroidal antiinflammatory agents (NSAID's) are useful in the treatment of macular degeneration.		

Best Available Copy

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Best Available Copy

- 1 -

TITLE OF THE INVENTIONUSE OF NON-STEROIDAL ANTIINFLAMMATORY AGENTS IN  
MACULAR DEGENERATION

5           Senile macular degeneration is one of the most common  
causes of reduction of vision after the age of 65. The condition is  
chronic with a progressive course. Even though some of the  
pathophysiological changes in the retina are known, the actual cause of  
the disease is not known, nor has there as yet been developed a  
10       treatment with convincing effects.

          During the development of senile macular degeneration an  
increased permeability of the retinal pigment epithelium and the retinal  
capillaries are seen, with efflux of fluid and probably of tissue active  
substances which participate in the degeneration of tissue and the later  
15       scarification that takes place.

          There is a well documented effect of Indomethacin in the  
treatment of cystoid macular oedema, a condition, as in senile macular  
degeneration, in which there is an increased permeability of the retinal  
capillaries and some destruction of retinal pigment epithelium.

20           Now with this invention, there is provided a novel method  
of treating macular degeneration by the topical administration to the eye  
of an effective amount of an NSAID.

          The preferred NSAID for purposes of this novel method of  
treatment is indomethacin, but others of comparable antiinflammatory  
activity which are compatible with ophthalmic use are also useful.  
25       These include the following: diclofenac, ketorolac, flurbiprofen and the  
like.

          The NSAID is applied topically to the eye in an  
ophthalmologically acceptable formulation in the form of an aqueous  
suspension or solution, an ointment, a gel or an aqueous solution which  
30       gels on contact with the eye. An aqueous solution or suspension is the  
preferred formulation and has about 1 to about 15 mg of NSAID per ml  
of formulation, preferably about 10 mg/ml.

Best Available Copy

- 2 -

In addition to the medicament, flocculating and deflocculating agents and water, conventional excipients and other materials are advantageously employed in preparing the ophthalmic suspension compositions of the present invention in accordance with good pharmaceutical practice. For example, the ophthalmic suspensions are sterile and preferably contain a bacteriological preservative to maintain sterility during use. Quarternary ammonium bacteriostats such as benzalkonium chloride may be used as well as phenyl mercuric acetate, phenyl mercuric nitrate, thimerosal, benzyl alcohol, or  $\beta$ -phenylethyl alcohol. These bacteriostats may suitably be used in a range of from 0.01 to 3.0 mg/ml and preferably 0.1 to 0.2 mg/ml of total suspension. An anti-oxidant may also be used to prevent oxidation of the medicament. Suitable anti-oxidants include sodium bisulfite, N-acetyl cysteine salts, sodium ascorbate, sodium metabisulfite, sodium acetone bisulfite and other acceptable anti-oxidants known to the pharmaceutical art. These anti-oxidants may suitably be used in a range of 0.1 to 10.0 mg/ml and preferably 0.2 to 3.5 mg/ml. In conjunction with the anti-oxidants, chelating agents such as disodium edetate may also be employed.

Viscosity inducing agents helpful in suspension characteristics of the composition, including cellulose derivatives such as hydroxymethyl cellulose, hydroxypropyl cellulose and methyl cellulose, may also be used in the formulation. For this purpose, one may use from 5.0 to 10.0 mg/ml and preferably from 1.5 to 3.5 mg/ml of such agents. Lecithin may also be used to provide helpful suspension characteristics for the ophthalmic suspension composition, being employed for this purpose in amounts of from 0.05 to 1.0 mg/ml of total suspension, and preferably from 0.1 to 0.4 mg/ml. A humectant is also sometimes used to help retain the water of the formulation in the eye. High molecular weight sugars are suitably used for this purpose such as sorbitol and dextrose in a concentration of from 0.1 to 10.0 mg/ml and especially 0.5 to 2.0 mg/ml. Finally, since the formulation is autoclaved to obtain initial sterility an autoclaving aid such as sodium chloride is normally added to the formulation.

Best Available Copy

- 3 -

The novel method of treatment of this invention comprises the topical ocular administration of 1 or 2 drops of the formulation 2 to 4 times a day.

5 A typical formulation for use in the novel method of treatment of this invention is a suspension of indomethacin, the preparation of which is described below:

The following procedures were followed in preparation of a 5 L batch of an acceptable ophthalmic suspension in accordance with the present invention, of 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl acetic acid. The therapeutic dosage concentration of the total  
10 final batch was 10 mg/ml of medicament in the total suspension. However, dosage concentrations of the medicament of 5 mg/ml and 2.5 mg/ml may also be prepared following the same procedures, varying only the initial amount of medicament employed, proportionally to yield the resultant smaller dosage concentrations. A first mixture (I) was  
15 prepared by mixing in a 1250 ml bottle: 1 g sodium bisulfite, 30 g NaCl, 70 ml water, and 51.5 g 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl acetic acid. A second mixture (II) was prepared by dissolving 1 g of lecithin in 225 ml water. A third (III) mixture was  
20 prepared by admixing 7.5 g of hydroxyethylcellulose in 1.5 L water, and bringing the total volume to 2.0 L after the initial mixture clarified. Finally, a fourth mixture (IV) of the remaining suspension ingredients was prepared by admixing 1.88 g polyoxyethylene (20) sorbitan monooleate, 1.0 g benzalkonium chloride, 12.5 g benzyl alcohol, 12.5 g  
25  $\beta$ -phenylethyl alcohol, 50.0 g of sorbitol as aqueous solution, and 2.5 g disodium edetate. All four mixtures were sterilized by autoclaving for 30 minutes at 121°C under 15 psig. Then, mixture II was added to I, and this mixture, in turn, was added to mixture III. Finally, mixture IV was added aseptically to the mixture of I, II and III by way of sterilizing  
30 membrane, and the total suspension volume was brought to 5 L with sterile water. The suspension was homogenized at 1500 psig and filled into containers.

Best Available Copy

- 4 -

WHAT IS CLAIMED IS:

1. A method of treating macular degeneration which  
comprises the topical ocular administration to a patient in need of such  
treatment of an effective amount of an NSAID.

5

2. The method of Claim 1, wherein the NSAID is  
selected from the group consisting of indomethacin, diclofenac,  
ketorolac and flurbiprofen.

10

3. The method of Claim 2 wherein the NSAID is  
indomethacin.

15

20

25

30

Best Available Copy

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/02786

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 31/19, 31/21, 31/40

US CL :514/419, 420, 513, 568, 912

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/419, 420, 513, 568, 912

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A, 4,087,538 (PORTNOFF) 02 May 1978, entire document.	1-3

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

13 JUNE 1994

Date of mailing of the international search report

JUN 23 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ZOHREH FAY

Telephone No. (703) 308.1235

Best Available Copy